Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?-the shifting paradigm of therapeutics

Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S39-S45. doi: 10.21037/tlcr.2018.01.06.

Authors

Malinda Itchins^{1

2

3}, Stephen Clarke^{1

2

3

4}, Nick Pavlakis^{1

2

3

4}

Affiliations

¹ Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, St Leonards, NSW, Australia.
² Northern Clinical School, University of Sydney, NSW, Australia.
³ Northern Cancer Institute, St Leonards, NSW, Australia.
⁴ Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW, Australia.

No abstract available

Publication types

Editorial
Comment